San Francisco-based Olema and Aurigene Discovery Technologies, a wholly-owned unit of Dr. Reddy’s Laboratories of Hyderabad, India have inked an exclusive global license agreement to research, develop, and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for the rights to a pre-existing Aurigene program.
Aurigene will be eligible for up to $60 million in potential clinical development and regulatory milestones and up to $370 million in potential commercial milestones, as well as royalties ranging from the mid-single digits to the low double digits based on annual net sales.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts. Olema and Aurigene will jointly direct further preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.
Sean P. Bohen, president and Chief Executive Officer of Olema Oncology, noted, “We believe this is a strong strategic opportunity to enhance our growing discovery portfolio.
Murali Ramachandra CEO of Aurigene said, “This agreement with Olema further validates Aurigene’s proven expertise in discovery and preclinical development of effective cancer therapeutics.”
Last updated: December 26th, 2025
